|
1
|
Gentry-Maharaj A and Menon U: Screening
for ovarian cancer in the general population. Best Pract Res Clin
Obstet Gynaecol. 26:243–256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klint A, Tryggvadóttir L, Bray F, et al:
Trends in the survival of patients diagnosed with cancer in female
genital organs in the Nordic countries 1964-2003 followed up to the
end of 2006. Acta Oncol. 49:632–643. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Permuth-Wey J and Sellers TA: Epidemiology
of ovarian cancer. Methods Mol Biol. 472:413–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zahedi P, Yoganathan R, Piquette-Miller M
and Allen C: Recent advances in drug delivery strategies for
treatment of ovarian cancer. Expert Opin Drug Deliv. 9:567–583.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shih IeM and Davidson B: Pathogenesis of
ovarian cancer: clues from selected overexpressed genes. Future
Oncol. 5:1641–1657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bulun SE: Uterine fibroids. N Engl J Med.
369:1344–1355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Groenen LC, Nice EC and Burgess AW:
Structure-function relationships for the EGF/TGF-alpha family of
mitogens. Growth Factors. 11:235–257. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lemke G: Neuregulins in development. Mol
Cell Neurosci. 7:247–262. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berchuck A, Kamel A, Whitaker R, et al:
Overexpression of HER-2/neu is associated with poor survival in
advanced epithelial ovarian cancer. Cancer Res. 50:4087–4091.
1990.PubMed/NCBI
|
|
10
|
Berchuck A, Rodriguez G, Kinney RB, et al:
Overexpression of HER-2/neu in endometrial cancer is associated
with advanced stage disease. Am J Obstet Gynecol. 164:15–21. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tandon AK, Clark GM, Chamness GC, et al:
HER-2/neu oncogeneprotein and prognosis in breast cancer. J Clin
Oncol. 7:1120–1128. 1989.PubMed/NCBI
|
|
12
|
Meden H and Kuhn W: Overexpression of the
oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic
factor. Eur J Obstet Gynecol Reprod Biol. 71:173–179. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slamon DJ, Clark GM, Wong SG, et al: Human
breast cancer: correlation ofrelapse and survival with
amplification of the HER-2/neu oncogene. Science. 235:177–182.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slamon DJ, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in humanbreast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carter P, Presta L, Gorman CM, et al:
Humanization of an anti-p185HER2 antibody for human cancer therapy.
In: Proc Natl Acad Sci USA. 89. pp. 4285–4289. 1992; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Verma S, Miles D, Gianni L, et al: EMILIA
Study Group: Trastuzumab emtansine for HER2-positive advanced
breast cancer. N Engl J Med. 367:1783–1791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Y, Zhang Y, Wang M, et al:
Downregulation of HER3 by a novel antisenseoligonucleotide,
EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine
kinase inhibitors in animal models. Mol Cancer Ther. 12:427–437.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tai W, Mahato R and Cheng K: The role of
HER2 in cancertherapy and targeted drug delivery. J Control
Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferracin M, Bassi C, Pedriali M, et al:
miR-125b targetserythropoietin and itsreceptor and their expression
correlates with metastaticpotential and ERBB2/HER2 expression. Mol
Cancer. 12:1302013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Corsi F, Fiandra L, De Palma C, et al:
HER2 expression in breast cancer cells is downregulated upon active
targeting by antibody-engineered multifunctional nanoparticles in
mice. ACS Nano. 5:6383–6393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rho O, Kim DJ, Kiguchi K and Digiovanni J:
Growth factor signaling pathways as targets for prevention of
epithelial carcinogenesis. Mol Carcinog. 50:264–279. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Campone M, Noël B, Couriaud C, et al:
c-Myc dependent expression of pro-apoptotic Bim renders
HER2-overexpressing breast cancer cells dependent on anti-apoptotic
Mcl-1. Mol Cancer. 10:1102011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maillard PV, Ciaudo C, Marchais A, et al:
Antiviral RNA interference in mammalian cells. Science.
342:235–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mutch DG and Prat J: 2014 FIGO staging
forovarian, fallopiantube and peritoneal cancer. Gynecol Oncol.
133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitativePCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
World Health Organization, . GLOBOCAN
2012: Estimated Cancer Incidence and Mortality Worldwide in 2012.
http://globocan.iarc.frDecember
12–2013
|
|
27
|
Jemal A, Tiwari RC, Murray T, et al:
American Cancer Society: Cancerstatistics, 2004. CA Cancer J Clin.
54:8–29. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Buys SS, Partridge E, Black A, et al: PLCO
Project Team: Effect of screening on ovarian cancer mortality: the
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening
Randomized Controlled Trial. JAMA. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Colombo N, Peiretti M, Parma G, et al:
ESMO Guidelines Working Group: Newlydiagnosed and relapsed
epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines
fordiagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5):
S23–S30. 2010. View Article : Google Scholar
|
|
31
|
du Bois A, Lück HJ, Meier W, et al:
Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study
Group: A randomized clinical trial of cisplatin/paclitaxel versus
carboplatin/paclitaxel as first-line treatment of ovarian cancer. J
Natl Cancer Inst. 95:1320–1329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Levanon K, Crum C and Drapkin R: New
insights into the pathogenesis of serous ovarian cancer and its
clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Steffensen KD, Waldstrøm M, Jeppesen U, et
al: The prognostic importance of cyclooxygenase 2 and HER2
expression in epithelial ovarian cancer. Int J Gynecol Cancer.
17:798–807. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Colombo PE, Fabbro M, Theillet C, et al:
Sensitivity and resistance to treatment in the primary management
of epithelial ovarian cancer. Crit Rev Oncol Hematol. 89:207–216.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Berchuck A, Kamel A, Whitaker R, et al:
Overexpression of HER-2/neu is associated with poor survival in
advanced epithelial ovarian cancer. Cancer Res. 50:4087–4091.
1990.PubMed/NCBI
|
|
36
|
Chao WR, Lee MY, Lin WL, et al: HER2
amplification and overexpression are significantly correlated in
mucinous epithelial ovarian cancer. Hum Pathol. 45:810–816. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shawver LK, Slamon D and Ullrich A: Smart
drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell.
1:117–123. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rao DD, Vorhies JS, Senzer N and
Nemunaitis J: siRNA vs. shRNA: similarities and differences. Adv
Drug Deliv Rev. 61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Faltus T, Yuan J, Zimmer B, et al:
Silencing of the HER2/neu gene by siRNA inhibitsproliferation and
induces apoptosis in HER2/neu-overexpressing breast cancer cells.
Neoplasia. 6:786–795. 2004. View Article : Google Scholar : PubMed/NCBI
|
